MAP Pharmaceuticals is a biopharmaceutical company concentrated on addressing the development and commercialization of novel therapies to patients’ needs in neurology focused.MAP Pharmaceuticals intends to use the proceeds from this offering for general corporate purposes and commercialization efforts for LEVADEX, orally inhaled orally inhaled investigational drug for the acute treatment of migraine.

U.S. $ Underwriter exercises possibility of additional common shares[ Professional Services Close – Up] BuyBofA Merrill Lynch acted as sole book-running managers for the offering.Has closed According to a release, the issue of additional shares, and all MAP Pharmaceuticals MAP Pharmaceuticals. The total gross proceeds were approximately $ 59, and the total net proceeds of approximately U.S. $ 56, net of underwriting discounts and commissions.‘by courtesy of They , the whole Kaiser Daily Health Policy view Reports looking the archives and log of D -mail delivery of Emperor Daily Health policy coverage strongly committed royal network. A free service of The Henry J. Released. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.